Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Biota Pharmaceuticals Inc    NABI   US6295191091

Business Summary
Operates as an anti-infective drug development company

Biota Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery and development of products to prevent and treat serious and potentially life-threatening infectious diseases.

The Company currently has two Phase 2 clinical-stage product candidates in development: laninamivir octanoate, a long-acting neuraminidase inhibitor that the Company is developing for the treatment of influenza A and B infections under an investigational new drug application (IND) in the United States through a contract with the U.S. Office of Biomedical Advanced Research and Development Authority (BARDA) that is designed to provide up to $231 million in financial support to complete its clinical development; and vapendavir, a potent, oral broad spectrum capsid inhibitor of enteroviruses, including human rhinovirus (HRV).

In addition to these clinical-stage programs, the Company has a preclinical program focused on developing treatments for respiratory syncytial virus (RSV).

Biota Pharmaceuticals was founded on November 8, 2012 and is headquartered in Alpharetta, GA.
Officers and Executives
NameAgeOfficer SinceTitle
Russell H. Plumb MBA, CPA54-President, CEO, CFO, Secretary & Treasurer
James Charles Fox, PhD62-Chairman
John Nicholas Lambert, PhD--Vice President-Product Development & Operations
Anna Novotney-Barry--Vice President-Clinical Development
Simon P. Tucker, PhD--Vice President-Research & Business Development
Geoffrey F. Cox, PhD69-Independent Non-Executive Director
Richard James Hill66-Independent Non-Executive Director
Anne M. VanLent65-Independent Non-Executive Director
Michael R. Dougherty55-Independent Non-Executive Director
John P. Richard, MBA56-Independent Non-Executive Director
Surperformance© rating of Biota Pharmaceuticals Inc
Overall rating In sector In country
Trading Rating - - -
Investor Rating - - -
Growth (Revenue) - - -
Valuation - - -
Finances - - -
Profitability - - -
Earnings quality
Business Predictability - - -
PER - - -
Potential - - -
Yield - - -
Consensus - - -
7 days EPS revision - - -
4 months EPS revision - - -
1 year EPS revision - - -
4 months Revenue revision - - -
1 year Revenue revision - - -
More Ratings
Biotechnology / Pharmaceuticals
 Biotechnology / Pharmaceuticals
  Pharmaceuticals - Generic / Specialty
Sector Pharmaceuticals - Generic / Specialty
Trading RatingInvestor Rating
Sector Pharmaceuticals - Generic / Specialty
Company contact information
Biota Pharmaceuticals, Inc.
2500 Northwinds Parkway
Suite 100
Alpharetta, GA 30009

Phone : +1.678.221.3343
Web :
© 2014 Factset   
Dynamic quotes